T. Xiao
4 Papers
T. Xiao is an academic researcher. The author has contributed to research in topics: Medicine & Cancer research. The author has an hindex of 1, co-authored 3 publications.
Chat about Author
Papers
Integrated Machine Learning and Bioinformatic Analyses Constructed a Novel Stemness-Related Classifier to Predict Prognosis and Immunotherapy Responses for Hepatocellular Carcinoma Patients
Dongni Chen,Jixing Liu,Longjun Zang,T. Xiao,Xianlin Zhang,Zheng Li,Hongwei Zhu,Wenzhe Gao,Xiao Yu +8 more
TL;DR: Wang et al. as discussed by the authors proposed a novel CSCs-related cluster of hepatocellular carcinoma (HCC) to predict patients' response to immunotherapy, and four machine learning algorithms (LASSO, RF, SVM-RFE and XGboost) were applied to distinguish different stemness subtypes.
Interplay of four types of RNA modification writers revealed distinct tumor microenvironment and biological characteristics in pancreatic cancer
Wenzhe Gao,Dongni Chen,Jixing Liu,Longjun Zang,T. Xiao,Xianlin Zhang,Zheng Li,Hongwei Zhu,Xiao Yu +8 more
TL;DR: Wang et al. as mentioned in this paper investigated the interplay mechanism of these writers in immunogenomic features and molecular biological characteristics in pancreatic cancer, and classified patients into two distinct RNA modification patterns (WM_score_high and _low).
Risk factors analysis and establishment of predictive nomogram of extranodal B-cell lymphoma of mucosal-associated lymphoid tissue.
J. Hua,Zheng Lia,C. Ma,X. Zhang,Q. Li,Xiaomin Duan,T. Xiao,X. Geng +7 more
TL;DR: In this paper , the authors explored the factors associated with the performance of radiotherapy and assessed its prognostic impact in patients with MALT lymphoma, and showed that radiotherapy is significantly associated with a better prognosis in patients having early but not advanced MALT.
LncRNA HOXA‑AS2 is a prognostic and clinicopathological predictor in patients with cancer: A meta‑analysis
T. Xiao,An Yan,Lifang Tan,Hongwei Zhu +3 more
TL;DR: In conclusion, elevated expression of lncRNA HOXA-AS2 was significantly related to poor clinical outcomes in various cancer types, such as osteosarcoma, non-small cell lung cancer and papillary thyroid carcinoma, a finding that was further confirmed by the present study.